Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.

Proteasome inhibitors

Proteasome inhibitors in the glossary for Waldenström's macroglobulinemia

Drugs that block the action of proteasomes (cellular complexes that break down proteins)

The ubiquitin proteasome pathway is a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins. Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death. Thus inhibition of the proteosome can shift this equilibrium towards cell death. Three proteasome inhibitors have received regulatory approval and are used routinely in clinical settings, including bortezomib, carfilzomib and ixazomib.1

Glossary overview


1.Manasanch EE and Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 2017: 14;417–433.
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.